ADR Therapeutics Initiates Joint Research on "Neocella" with Exosome Expert Prof. Takahiro Ochiya of Tokyo Medical University

ADR Therapeutics, a subsidiary of ADR120S, has entered into a joint research agreement with Tokyo Medical University to study "Neocella," a promising new extracellular vesicle platform. The research is led by Professor Takahiro Ochiya, a leading global authority in exosome research. The collaboration aims to evaluate Neocella's biological functions, clarify its mechanisms, explore its application in animal inflammatory diseases like endometritis, and establish a stable manufacturing process for future practical use.